Cargando…

Update on Melasma—Part II: Treatment

Melasma is a prevalent chronic relapsing pigmentary disorder that affects photoexposed areas, especially in women of childbearing age. Although there is currently no curative treatment available for melasma, this manuscript critically reviews the knowledge regarding photoprotection, topical and oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassiano, Daniel P., Espósito, Ana Cláudia C., da Silva, Carolina N., Lima, Paula B., Dias, Joana A. F., Hassun, Karime, Miot, Luciane D. B., Miot, Hélio A., Bagatin, Ediléia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464276/
https://www.ncbi.nlm.nih.gov/pubmed/35906506
http://dx.doi.org/10.1007/s13555-022-00780-4
_version_ 1784787547709243392
author Cassiano, Daniel P.
Espósito, Ana Cláudia C.
da Silva, Carolina N.
Lima, Paula B.
Dias, Joana A. F.
Hassun, Karime
Miot, Luciane D. B.
Miot, Hélio A.
Bagatin, Ediléia
author_facet Cassiano, Daniel P.
Espósito, Ana Cláudia C.
da Silva, Carolina N.
Lima, Paula B.
Dias, Joana A. F.
Hassun, Karime
Miot, Luciane D. B.
Miot, Hélio A.
Bagatin, Ediléia
author_sort Cassiano, Daniel P.
collection PubMed
description Melasma is a prevalent chronic relapsing pigmentary disorder that affects photoexposed areas, especially in women of childbearing age. Although there is currently no curative treatment available for melasma, this manuscript critically reviews the knowledge regarding photoprotection, topical and oral therapies, and procedures such as peelings, laser, and microneedling that represent the main strategies for control and prevention of this disease. As the pathogenesis of melasma is not entirely understood, there are prospects for the development of new therapeutic strategies that might act on the pathways that promote sustained pigmentation rather than merely decreasing melanin synthesis and removing melanin from the epidermis.
format Online
Article
Text
id pubmed-9464276
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-94642762022-09-12 Update on Melasma—Part II: Treatment Cassiano, Daniel P. Espósito, Ana Cláudia C. da Silva, Carolina N. Lima, Paula B. Dias, Joana A. F. Hassun, Karime Miot, Luciane D. B. Miot, Hélio A. Bagatin, Ediléia Dermatol Ther (Heidelb) Review Melasma is a prevalent chronic relapsing pigmentary disorder that affects photoexposed areas, especially in women of childbearing age. Although there is currently no curative treatment available for melasma, this manuscript critically reviews the knowledge regarding photoprotection, topical and oral therapies, and procedures such as peelings, laser, and microneedling that represent the main strategies for control and prevention of this disease. As the pathogenesis of melasma is not entirely understood, there are prospects for the development of new therapeutic strategies that might act on the pathways that promote sustained pigmentation rather than merely decreasing melanin synthesis and removing melanin from the epidermis. Springer Healthcare 2022-07-29 /pmc/articles/PMC9464276/ /pubmed/35906506 http://dx.doi.org/10.1007/s13555-022-00780-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Cassiano, Daniel P.
Espósito, Ana Cláudia C.
da Silva, Carolina N.
Lima, Paula B.
Dias, Joana A. F.
Hassun, Karime
Miot, Luciane D. B.
Miot, Hélio A.
Bagatin, Ediléia
Update on Melasma—Part II: Treatment
title Update on Melasma—Part II: Treatment
title_full Update on Melasma—Part II: Treatment
title_fullStr Update on Melasma—Part II: Treatment
title_full_unstemmed Update on Melasma—Part II: Treatment
title_short Update on Melasma—Part II: Treatment
title_sort update on melasma—part ii: treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464276/
https://www.ncbi.nlm.nih.gov/pubmed/35906506
http://dx.doi.org/10.1007/s13555-022-00780-4
work_keys_str_mv AT cassianodanielp updateonmelasmapartiitreatment
AT espositoanaclaudiac updateonmelasmapartiitreatment
AT dasilvacarolinan updateonmelasmapartiitreatment
AT limapaulab updateonmelasmapartiitreatment
AT diasjoanaaf updateonmelasmapartiitreatment
AT hassunkarime updateonmelasmapartiitreatment
AT miotlucianedb updateonmelasmapartiitreatment
AT miothelioa updateonmelasmapartiitreatment
AT bagatinedileia updateonmelasmapartiitreatment